Research programme: Ewing's sarcoma therapeutics - Nanovalent Pharmaceuticals

Drug Profile

Research programme: Ewing's sarcoma therapeutics - Nanovalent Pharmaceuticals

Alternative Names: FEZF1-AS1-specific antisense oligonucleotide - Nanovalent Pharmaceuticals; FEZF1-AS1-specific ASO - Nanovalent Pharmaceuticals

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NanoValent Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Histone modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ewing's sarcoma

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Ewing's sarcoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 31 Dec 2016 Preclinical trials in Ewing's Sarcoma in USA (Parenteral)
  • 31 Dec 2016 Nanovalent Pharmaceuticals receives STTR grant from the US department of Health and Human Services for development of targeted nanoparticles in Ewing's sarcoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top